Is there a need for HCV resistance testing in routine diagnostics and patient treatment? -Routine HCV genotyping and resistance testing and performance of the Sentosa SQ HCV Genotyping v2.0 assay

BACKGROUND

The need of HCV resistance testing in routine diagnostics is still a subject of debate. We evaluated the recently updated Sentosa® SQ HCV Genotyping Assay v2.0 from Vela diagnostics, a next generation sequencing (NGS)-based assay for identification of HCV genotypes 1 to 6 and detection of resistance associated substitutions (RAS) in HCV genotypes 1a/1b and 3. We used the research use only assay for genotyping and resistance detection in the NS3, NS5A and NS5B genes of HCV for samples within the PEPSI study(1). The further enhancement of version 2 geno2pheno is the extended length of sequence for NS5B starting at aminoacid (aa) 1 (instead of aa 339 in version 1) up to aa 565, and the inclusion of genotype 3 in resistance analysis.

METHODS

274 samples (so far) were analyzed with the HCV version 2 assay. The assay is validated by Vela for viral loads above 1000 IU/ml. Beside the included analysis in the Vela system (quality-controls, reads, coverage, genotype, RAS and variant frequency Figs 1 and 2) we reinterpreted the alignment files of the lonTorrent using the torrent suite (5.6) to map the sequences (s. Fig.3). We generated then consensus sequences with a minimum of 100 / 20 / 4 reads for each base with individual minority cut-offs at 30 / 20 / 15 / 10 / 5 and 2%. Sequence-interpretation was performed with the 0.92 online [hcv] tool (http://hcv.geno2pheno.org), see Fig 4. Sequence quality, predicted genotypes, success rates per genotype and resistance mutations for NS3, NS5A and **NS5B** were analyzed.

RESUITS


Run Info		Invalid Samples					Ci
Name	080318_HCV_NGS_AM	There are no invalid samples					Si proc
Run Date	Mar 9, 2018 5:51:38 PM						proc
Assay	16_Sentosa_SQ_HCV_Genotyping_Assay_v2	ISP Density	ISP S	ummary			
Reference	HCV_v2_ref	080318_HCV_NGS_AM Loading Density (Avg ~ 80%)					
Key Signal	♥ 86	Loading Density (Avg = 50.%)	100 %				Identify
Loading%	♥ 80.11			0% 9,054,761	20 ⁰ Empty V		sequenc
Chip Type	318DX	800	- 80 %	10 III III III III III III III III III I			na ma
Machine	SQSuite_sn274680017	And I have a little of the lit		0% 9,037,866	0% No Template		
Bases			50%	9% 6,216,074	31%		Remap
Total Valid Bases (Run Throughput)	◙ 656,746,801	⁶ 400		onal	Polyclonal		sequence in prev
Mapped Bases	635,191,300 (96.72%)	200	7	1% 4,408,040	2% Adapter Dimer 27% Low Quality		
Unmapped Bases	21,555,501 (3.28%)		10 %	Library	2770 Low Quanty		
		0	0 %				
Reads		0 100 200 300 400 500 600 700 800 3392 wells					
inal Library	4,408,040						
nvalid Reads	53,273 (1.21%)						
nvalid Sample Reads	0 (0.00%)						
otal Valid Reads	4,354,767					F	Fia 3º MIB
Mapped Reads	4,354,767 4,284,993 (98.40%)					F	-ig 3: MIB
Mapped Reads Unmapped Reads 2013 Vela Diagnostic	4,284,993 (98.40%)				geno2p		ig 3: MIB
Mapped Reads Unmapped Reads 2013 Vela Diagnostic	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved.				HCV resistance prediction fi	pheno®	
Mapped Reads Unmapped Reads 2013 Vela Diagnostic	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics			10% minority	HCV resistance prediction fr	pheno®	
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics			10% minority	HCV resistance prediction fr Cut-Off	pheno® from genotype (version 1.(
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics	Genomic Target Median Co	verage	Patient: Birth date:	HCV resistance prediction fr Cut-Off	pheno® from genotype (version 1.0 information Study ID: Viral load:	
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Its: Subtype Contig Name SentosaBC-5.1a.NS3.re	epc1 NS3	488	Patient:	HCV resistance prediction fr Cut-Off	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected:	
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Its: Subtype Contig Name	ep.c1 NS3 rep.c1 NS5A		Patient: Birth date: Sample received: Sample ID:	HCV resistance prediction f Cut-Off I. General ii 1067361620_2018021309 2452_HCV_NS5B_100_1 0	from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype:	0) NS5B: 1b (91.15%)
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Fig 1: run tigs HCV Genotype/	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Its: Subtype Contig Name SontosaBC-5.1a.NS3.rc SontosaBC-5.1a.NS3.rc	ep.c1 NS3 rep.c1 NS5A	488 480	Patient: Birth date: Sample received:	HCV resistance prediction f Cut-Off I. General ii 1067361620_2018021309 2452_HCV_NS5B_100_1 0	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected:	0)
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Fig 1: run tigs HCV Genotype/	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Its: Subtype Contig Name SontosaBC-5.1a.NS3.rc SontosaBC-5.1a.NS3.rc	ap.c1 NS3 rep.c1 NS5A rep.c1 NS5B	488 480 460	Patient: Birth date: Sample received: Sample ID: Sample type:	HCV resistance prediction f Cut-Off I. General ii 1067361620_2018021309 2452_HCV_NS5B_100_1 0	from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date:	0) NS5B: 1b (91.15%)
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Fig 1: run tigs HCV Genotype/ Ia rget Variants	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Statistics Subtype Contig Name SentosaBC-5.1a.NS5A. SentosaBC-5.1a.NS5B.	op.c1 NS3 rep.c1 NS5A rep.c1 NS5B AA Mutation Detected Coverage Variant Fre	488 480 460	Patient: Birth date: Sample received: Sample ID: Sample type:	HCV resistance prediction f Cut-Off I. General ii 1067361620_2018021309 2452_HCV_NS5B_100_1 0	from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Reported by:	0) NS5B: 1b (91.15%)
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run tailed Resul ontigs HCV Genotype/ 1a rget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Statistics Subtype Contig Name SentosaBC-5.1a_NS3.rd SentosaBC-5.1a_NS5B. Position Genomic Target 3657 NS3	AA Mutation Detected Coverage Variant Fre 80K 1936 9	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NSSB codons covered	HCV resistance prediction fr Cut-Off I. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1 - 565	from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information	0) NS5B: 1b (91.15%) 20.02.2018
Mapped Reads Unmapped Reads 2013 Vela Diagnostic ig 1: run tig 1: run taled Resul ontigs HCV Genotype/ 1 1a rget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician:	HCV resistance prediction fr Cut-off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-585 M57L_D82AD, R85QR, K81KR, V A218AS, S231N, R254KR, S338N K523KR, S549G, L564LV	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information	0) NS5B: 1b (91.15%) 20.02.2018
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Etailed Resul ontigs HCV Genotype/ 1 1a rget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Statistics Subtype Contig Name SentosaBC-5.1a_NS3.rd SentosaBC-5.1a_NS5B. Position Genomic Target 3657 NS3	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t.	HCV resistance prediction fr Cut-off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-585 M57L_D82AD, R85QR, K81KR, V A218AS, S231N, R254KR, S338N K523KR, S549G, L564LV	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information	0) NS5B: 1b (91.15%) 20.02.2018
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Etailed Resul ontigs HCV Genotype/ 1 1a rget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t. EU781827)	HCV resistance prediction fr Cut-off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-585 M57L_D82AD, R85QR, K81KR, V A218AS, S231N, R254KR, S338N K523KR, S549G, L564LV	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information	0) NS5B: 1b (91.15%) 20.02.2018
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Etailed Resul ontigs HCV Genotype/ 1 1a rget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t. EU781827)	HCV resistance prediction fr Cut-Off I. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1 - 565	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information	0) NS5B: 1b (91.15%) 20.02.2018
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Etailed Resul ontigs HCV Genotype/ 1a Inget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t. EU781827)	HCV resistance prediction fr Cut-off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-585 M57L_D82AD, R85QR, K81KR, V A218AS, S231N, R254KR, S338N K523KR, S549G, L564LV	Information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information V86I, Q80K, R88KR, R120NS, K1240 KNS, P3607, T377S, E440EG, C4 V86I, Q80K, R88KR, R120NS, K1240 C485, S62AD, Q650R, V71M, A3 R113S, A117N, N120NS, K1240 C485, S62AD, Q650R, V71M, A3 R113S, R1540, T562V, V504L	NS5B: 1b (91.15%) 20.02.2018 (1240, Q127L, C213NST, 451CY, V409A, A513S, T520IV,
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Etailed Resul ontigs HCV Genotype/ 1a Inget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t. EU781827) NS5B region (w.r.t. H77) Drug Predi	HCV resistance prediction fr Cut-Off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-565 M57L_D82AD, R85QR, K81KR, V A218AS, S231N, R254KR, S338N K523KR, S49G, L564LV S6T, V11, Q19S, L36M, S39A, C K98KR, C110N, H11L, A112S, R Q206N, T219NST, S218AS, S231 R270K, E272Q, 1297L, R300S, G V432J, 143L, R436Q, U437E, E4 R514Q, I520IV, K523KR, A540P, III. Resistan iction	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information V85I, Q00K, R08KR, R120NS, K NS, P3507, T377S, E440EG, O4 C46S, S62AD, Q65QR, V71M, A3 R113S, A117N, N120NS, K124Q C46S, S62AD, Q65QR, V71M, A3 R13S, A137N, N328F, D34A, Q24 C46S, S62AD, Q65QR, V71M, A3 R13S, A117N, N120NS, K124Q C46S, S62AD, Q65QR, V71M, A3 R13S, A117N, N120NS, K124Q C46S, S62AD, Q65QR, V71M, A3 R14BC, Q44K, N444D, C54A, Q24 C46S, S62AD, Q65QR, V71M, A3 R14BC, Q44K, N444D, C54A, Q44K, N444D, C54A, Q44K, N444D, C54A, Q44K, N44A, C54A, Q44K, N44A, C54A, Q44K, N44A, C54A, Q44K, N44A, C54A, Q45A, Q4	0) NS5B: 1b (91.15%) 20.02.2018
Mapped Reads Unmapped Reads 2013 Vela Diagnostic Fig 1: run Etailed Resul ontigs HCV Genotype/ 1 1a rget Variants Reference NC.004102	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t. EU781827) NS5B region (w.r.t. H77) Drug Predi	HCV resistance prediction fr Cut-Off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-565 M57L_D82AD, R65QR, K81KR, V A218AS, S231N, R254KR, S335N K523KR, S49G, L664LV S67, 110, H11L, A112S, R 206N, 710N, H11L, A112S, R 206N, 713NST, S21BAS, S231 R270K, E272Q, 1297L, R300S, G V432I, 143L, R436Q, U437E, E4 R514Q, I520IV, K523KR, A540P, III. Resistan iction Scored position 44 451Y	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information V85I, Q90K, R98KR, R120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, A117N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R113N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R117N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R117N, N120NS, K1240 R113S, R113N, R113S, R117N, N120NS, K1240 R113S, R113N, R	0) NS5B: 1b (91.15%) 20.02.2018
Mapped Reads Unmapped Reads 2013 Vela Diagnostic ig 1: run tig 1:	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t. EU781827) NS5B region (w.r.t. H77) Drug Prediin Dasabuvir substit	HCV resistance prediction fr Cut-Off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-565 M57L_D82AD, R65QR, K81KR, V A218AS, S231N, R254KR, S335N K523KR, S49G, L664LV S67, 110, H11L, A112S, R 206N, 710N, H11L, A112S, R 206N, 713NST, S21BAS, S231 R270K, E272Q, 1297L, R300S, G V432I, 143L, R436Q, U437E, E4 R514Q, I520IV, K523KR, A540P, III. Resistan iction Scored position 44 451Y	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information V85I, Q90K, R98KR, R120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, A117N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R113N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R117N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R117N, N120NS, K1240 R113S, R113N, R113S, R117N, N120NS, K1240 R113S, R113N, R	0) NS5B: 1b (91.15%) 20.02.2018
Unmapped Reads 2013 Vela Diagnostic Fig 1: run etailed Resul ontigs HCV Genotype/ 1a reget Variants Reference NC.004102 S5A region is sequent	4,284,993 (98.40%) 69,774 (1.60%) s. All Rights Reserved. Statistics Subtype Contig Name SentosaBC-5.1a_NS3.re SentosaBC-5.1a_NS5A_SentosaBC-5.1a_NS5B Position Genomic Target 3657 NS3 ced successfully. No drug resistance mutations	AA Mutation Detected Coverage Variant Fre 80K 1936 9 S were detected	488 480 460 eq. (%)	Patient: Birth date: Sample received: Sample ID: Sample type: Physician: NS5B codons covered NS5B region (w.r.t. EU781827) NS5B region (w.r.t. H77) Drug Prediin Dasabuvir substit	HCV resistance prediction fr Cut-Off 1. General in 1067361620_2018021309 2452_HCV_NS5B_100_1 0 II. Sequence 1-565 M57L_D82AD, R65QR, K81KR, V A218AS, S231N, R254KR, S335N K523KR, S49G, L664LV S67, 110, H11L, A112S, R 206N, 710N, H11L, A112S, R 206N, 713NST, S21BAS, S231 R270K, E272Q, 1297L, R300S, G V432I, 143L, R436Q, U437E, E4 R514Q, I520IV, K523KR, A540P, III. Resistan iction Scored position 44 451Y	pheno® from genotype (version 1.0 information Study ID: Viral load: Sample collected: Predicted subtype: Report date: Report date: Reported by: e information V85I, Q90K, R98KR, R120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, A117N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R113N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R117N, N120NS, K1240 C46S, S62AD, Q65QR, V71M, A3 R113S, R117N, N120NS, K1240 R113S, R113N, R113S, R117N, N120NS, K1240 R113S, R113N, R	0) NS5B: 1b (91.15%) 20.02.2018

(1) Kalaghatgi P, Sikorski AM, Knops E, et al. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. Menéndez-Arias L, ed. PLoS ONE. 2016;11(5):e0155869. doi:10.1371/journal.pone.0155869.




Robert Ehret, Andrew Moritz, Stefan Breuer, Marcel Schütze and Martin Obermeier

MIB Medizinisches Infektiologiezentrum Berlin, Contact: obermeier@mvz-mib.de



S pipeline for Vela




sequence interpretation by geno2pheno with 10% and 2% minority cut-off

RESULTS


Sequences for 274/276 samples could be generated, only missing two samples with low viral loads (<1000 IU/mL) and a low number of drop outs for single genes (NS3 25/274, NS5A 10/274 and NS5B 3/274) mainly in non-1, non-3 genotypes (s. Fig 5). Genotype distribution was 1a (101), 3a (80), 1b (51), 4d (16), 2b (10), 4a (8), 6a (3), 2a (2) and one of 1g, 2c, 2k, 4o and 4r each as shown in Fig 6. Overall NS3, NS5A and NS5B genes showed RAS in 21,9%, 16,8% and 9,9%, respectively. 33 of 51 1b genotype samples showed resistance, two samples were resistant to three classes. 50/100 genotype 1a samples had resistance mutations, mainly NS3 Q80K (35x) but also NS5A (12x 28VT and 7x 93HN) and NS5B (3x556G; 2x553V, 316Y and 556R). Twelve out of 80 samples with genotype 3a had NS5A mutations (6x 30K, 2x 30V and 6x 93H), except one 80K the genotype 3a samples had no NS3 or NS5B mutations. Overall 167 RAS were detected. (71, 60, 36 for NS3, NS5A and NS5B) including 35 RAS in minorities with a cut-off below 10% and greater than 2% of population.

Patient example 1



Patient example 2

34 years old, male HIV negative IVDU, HCV diagnosis 2008, IL28B: C/T HCV VL at treatment initiation: 3 100 000 IU/mL, genotype 3a therapy: Epclusa(Velpatasvir/Sofosbuvir) + Ribavirin for 12 weeks (treatment start 10.07.18)








Fig 5: success (%) per genotype and gene

CONCLUSIONS

The Sentosa® SQ HCV Genotyping Assay v2.0 performed excellent, even in samples with low viral load. Designed to genotype all HCV strains and RAS in genotype 1a/1b and 3 we got success rates per gene of 96,9% (21 failures / 696 sequenced genes). In non-1a/b or 3 genotypes the success rate was 81,3% (24/129). With regard to the high genetic variability of HCV and the diversity of its genotypes and subtypes this is an exceptionally good success rate, which is reached otherwise only by stepwise approach using multiple in-house protocols. While for many sequencing protocols to determine the occurrence of RASs the HCV genotype has to be known in advance, this assay allows to gather this information in one step. Launch of HCV version 2 assay as Research Use Only (RUO) kit was in August 2018. CE/IVD approval is expected Q1/2019. A further improved assay is in development and the required documents are compiled for FDA approval. FDA approval is planned for 2019. A relative high proportion of investigated sequences showed RAS at a minority cut-off of 10%. Lowering this cut-off didn't significantly increase the number of detected RAS. Those RAS led to restrictions for single drugs or whole drug-classes. The relatively high rates of RAS clearly indicate the necessity of resistance analyses before starting an HCV-therapy and in case of treatment failure to avoid therapy failures and unnecessary given drugs avoiding side-effects and costs.

